Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing κP and κP, κS‐Coordinated Ph2PCH2CH2CH2S(O)xPh (x=0–2) Ligands. Issue 7 (27th January 2014)
- Record Type:
- Journal Article
- Title:
- Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing κP and κP, κS‐Coordinated Ph2PCH2CH2CH2S(O)xPh (x=0–2) Ligands. Issue 7 (27th January 2014)
- Main Title:
- Anticancer Potential of (Pentamethylcyclopentadienyl)chloridoiridium(III) Complexes Bearing κP and κP, κS‐Coordinated Ph2PCH2CH2CH2S(O)xPh (x=0–2) Ligands
- Authors:
- Ludwig, Gerd
Ranđelović, Ivan
Maksimović‐Ivanić, Danijela
Mijatović, Sanja
Bulatović, Mirna Z.
Miljković, Djordje
Korb, Marcus
Lang, Heinrich
Steinborn, Dirk
Kaluđerović, Goran N. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Iridium(III) complexes of the type [Ir(η<sup>5</sup>‐C<sub>5</sub>Me<sub>5</sub>)Cl<sub>2</sub>{Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph‐κ<italic>P</italic>}] (<italic>x</italic>=0–2; <bold>1</bold>–<bold>3</bold>) and [Ir(η<sup>5</sup>‐C<sub>5</sub>Me<sub>5</sub>)Cl{Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph‐κ<italic>P</italic>, κ<italic>S</italic>}][PF<sub>6</sub>] (<italic>x</italic>=0–1; <bold>4</bold> and <bold>5</bold>) with 3‐(diphenylphosphino)propyl phenyl sulfide, sulfoxide, and sulfone ligands Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph were designed, synthesized, and characterized fully, including X‐ray diffraction analyses for complexes <bold>3</bold> and <bold>4</bold>. In vitro studies against human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast adenocarcinoma (MCF‐7), colon adenocarcinoma (SW480), and melanoma (518A2) cell lines provided evidence for the high biological potential of the neutral and cationic iridium(III) complexes. Neutral iridium(III) complex <bold>5</bold> proved to be the most active, with IC<sub>50</sub> values up to about 0.1 μ<sc>M</sc>, representing activities of up to one order of magnitude higher than cisplatin. Using 8505C cells, apoptosis was shown to be the main mechanism through which complex<abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <p>Iridium(III) complexes of the type [Ir(η<sup>5</sup>‐C<sub>5</sub>Me<sub>5</sub>)Cl<sub>2</sub>{Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph‐κ<italic>P</italic>}] (<italic>x</italic>=0–2; <bold>1</bold>–<bold>3</bold>) and [Ir(η<sup>5</sup>‐C<sub>5</sub>Me<sub>5</sub>)Cl{Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph‐κ<italic>P</italic>, κ<italic>S</italic>}][PF<sub>6</sub>] (<italic>x</italic>=0–1; <bold>4</bold> and <bold>5</bold>) with 3‐(diphenylphosphino)propyl phenyl sulfide, sulfoxide, and sulfone ligands Ph<sub>2</sub>PCH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>S(O)<sub><italic>x</italic></sub>Ph were designed, synthesized, and characterized fully, including X‐ray diffraction analyses for complexes <bold>3</bold> and <bold>4</bold>. In vitro studies against human thyroid carcinoma (8505C), submandibular carcinoma (A253), breast adenocarcinoma (MCF‐7), colon adenocarcinoma (SW480), and melanoma (518A2) cell lines provided evidence for the high biological potential of the neutral and cationic iridium(III) complexes. Neutral iridium(III) complex <bold>5</bold> proved to be the most active, with IC<sub>50</sub> values up to about 0.1 μ<sc>M</sc>, representing activities of up to one order of magnitude higher than cisplatin. Using 8505C cells, apoptosis was shown to be the main mechanism through which complex <bold>5</bold> exerts its tumoricidal action. The described iridium(III) complexes represent potential leads in the search for novel metal‐based anticancer agents.</p> </abstract> … (more)
- Is Part Of:
- ChemMedChem. Volume 9:Issue 7(2014:Jul.)
- Journal:
- ChemMedChem
- Issue:
- Volume 9:Issue 7(2014:Jul.)
- Issue Display:
- Volume 9, Issue 7 (2014)
- Year:
- 2014
- Volume:
- 9
- Issue:
- 7
- Issue Sort Value:
- 2014-0009-0007-0000
- Page Start:
- 1586
- Page End:
- 1593
- Publication Date:
- 2014-01-27
- Subjects:
- Pharmaceutical chemistry -- Periodicals
615.19005 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1860-7187 ↗
http://www3.interscience.wiley.com/cgi-bin/jhome/110485305 ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cmdc.201300479 ↗
- Languages:
- English
- ISSNs:
- 1860-7179
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3172.254000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 4358.xml